Complete Filing Data
Indivior Pharmaceuticals, Inc. reported Selling General And Administrative Expense of $634.00 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Indivior Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income * | $210.0M | $7.0M | -$126.0M | -$53.0M | $205.0M |
| Selling General And Administrative Expense | $634.0M | $612.0M | $565.0M | $431.0M | |
| Operating Income Loss | $262.0M | $38.0M | -$152.0M | ||
| Income Tax Expense Benefit | $29.0M | $13.0M | -$19.0M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $239.0M | $20.0M | -$145.0M | ||
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $6.0M | -$6.0M | $2.0M | -$6.0M | |
| Operating Expenses | |||||
| Deferred Income Tax Expense Benefit | -$46.0M | $7.0M | -$64.0M | ||
| Gross Profit | $994.0M | $957.0M | $919.0M | $749.0M | $664.0M |
| Revenue From Contract With Customer Excluding Assessed Tax | $1.24B | $1.19B | $1.09B | $901.0M | |
| Research And Development Expense Excluding Acquired In Process Cost | $97.0M | $107.0M | $116.0M | $74.0M | |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | $6.0M | -$6.0M | $2.0M | -$6.0M | |
| Interest Expense Nonoperating | $45.0M | $41.0M | $35.0M | $27.0M | |
| Cost Of Goods And Services Sold | $246.0M | $231.0M | $174.0M | $151.0M | |
| Comprehensive Income Net Of Tax | $216.0M | $1.0M | -$124.0M | -$50.0M | |
| Deferred Income Tax Assets Net | $323.0M | $277.0M | $286.0M | ||
| Asset Impairment Charges | $19.0M | $8.0M | $0.00 | $0.00 | |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | $0.00 | $1.0M | $162.0M | $0.00 | |
| Income Taxes Receivable | $2.0M | $33.0M | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|---|
| Net Income * | $42.0M | $18.0M | $47.0M | $21.0M | $22.0M | -$97.0M | $61.0M |
| Selling General And Administrative Expense | $155.0M | $158.0M | $132.0M | $175.0M | $142.0M | $152.0M | $143.0M |
| Operating Income Loss | $43.0M | $72.0M | $66.0M | $46.0M | $35.0M | -$118.0M | $75.0M |
| Income Tax Expense Benefit | -$5.0M | $44.0M | $11.0M | $17.0M | $8.0M | -$23.0M | $11.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | $37.0M | $62.0M | $59.0M | $38.0M | $30.0M | -$121.0M | $73.0M |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | $0.00 | $2.0M | $1.0M | $7.0M | $0.00 | -$3.0M | |
| Operating Expenses | $187.0M | $156.0M | $205.0M | $206.0M | $338.0M | $171.0M | |
| Deferred Income Tax Expense Benefit | -$2.0M | $3.0M | |||||
| Gross Profit | $230.0M | $250.0M | $221.0M | $241.0M | $220.0M | $246.0M | |
| Revenue From Contract With Customer Excluding Assessed Tax | $314.0M | $302.0M | $266.0M | $307.0M | $299.0M | $284.0M | |
| Research And Development Expense Excluding Acquired In Process Cost | $33.0M | $21.0M | $22.0M | $22.0M | $26.0M | $28.0M | |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | $0.00 | $2.0M | $1.0M | $7.0M | $0.00 | -$3.0M | |
| Interest Expense Nonoperating | $12.0M | $15.0M | $12.0M | $11.0M | $9.0M | $9.0M | |
| Cost Of Goods And Services Sold | $83.0M | $52.0M | $44.0M | $66.0M | $79.0M | $38.0M | |
| Comprehensive Income Net Of Tax | $43.0M | $20.0M | $49.0M | $29.0M | -$97.0M | $59.0M | |
| Deferred Income Tax Assets Net | $285.0M | $270.0M | $279.0M | ||||
| Asset Impairment Charges | $0.00 | $1.0M | |||||
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | $0.00 | $1.0M | |||||
| Income Taxes Receivable | $13.0M | $3.0M | $29.0M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2014 |
|---|---|---|---|---|---|---|
| Stockholders Equity | -$98.0M | -$337.0M | -$184.0M | -$15.0M | $121.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $195.0M | $319.0M | $316.0M | $774.0M | $1.10B | |
| Liabilities | $1.30B | $1.65B | $1.94B | $1.72B | $1.63B | |
| Assets | $1.20B | $1.32B | $1.76B | $1.77B | $1.83B | |
| Retained Earnings Accumulated Deficit | -$243.0M | -$443.0M | -$288.0M | -$1.30B | ||
| Share Repurchase Liability Increase Decrease In Equity | $10.0M | $13.0M | -$14.0M | -$9.0M | ||
| Other Assets Noncurrent | $27.0M | $39.0M | $36.0M | |||
| Liabilities Current | $914.0M | $924.0M | $1.28B | |||
| Liabilities And Stockholders Equity | $1.20B | $1.32B | $1.76B | |||
| Inventory Net | $153.0M | $167.0M | $126.0M | |||
| Assets Current | $652.0M | $827.0M | $1.26B | |||
| Accounts Payable And Accrued Liabilities Current | $250.0M | $216.0M | $195.0M | |||
| Repayments Of Long Term Debt | $17.0M | $240.0M | $12.0M | $3.0M | ||
| Short Term Investments | $0.00 | $1.0M | $94.0M | |||
| Property Plant And Equipment Net | $144.0M | $100.0M | $84.0M | |||
| Other Liabilities Noncurrent | $21.0M | $18.0M | $31.0M | |||
| Other Liabilities Current | $0.00 | $11.0M | $40.0M | |||
| Operating Lease Right Of Use Asset | $26.0M | $39.0M | $40.0M | |||
| Operating Lease Liability Noncurrent | $22.0M | $32.0M | $34.0M | |||
| Operating Lease Liability Current | $10.0M | $10.0M | $9.0M | |||
| Long Term Investments | $28.0M | $27.0M | $41.0M | |||
| Long Term Debt Noncurrent | $290.0M | $315.0M | $237.0M | |||
| Long Term Debt Current | $29.0M | $18.0M | $3.0M | |||
| Intangible Assets Net Including Goodwill | $2.0M | $6.0M | $13.0M | |||
| Equity Securities Fv Ni Unrealized Gain Loss | $0.00 | -$9.0M | $0.00 | $0.00 | ||
| Contract With Customer Refund Liability Current | $582.0M | $562.0M | $535.0M | |||
| Common Stock Value | $62.0M | $62.0M | $68.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Stockholders Equity | -$207.0M | -$257.0M | -$285.0M | -$310.0M | -$281.0M | -$161.0M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $445.0M | $510.0M | $372.0M | $288.0M | $302.0M | $248.0M |
| Liabilities | $1.62B | $1.71B | $1.66B | |||
| Assets | $1.42B | $1.45B | $1.38B | |||
| Retained Earnings Accumulated Deficit | -$346.0M | -$388.0M | -$406.0M | |||
| Share Repurchase Liability Increase Decrease In Equity | $10.0M | -$12.0M | $5.0M | $14.0M | ||
| Other Assets Noncurrent | $27.0M | $44.0M | $39.0M | |||
| Liabilities Current | $965.0M | $1.06B | $1.01B | |||
| Liabilities And Stockholders Equity | $1.42B | $1.45B | $1.38B | |||
| Inventory Net | $155.0M | $149.0M | $163.0M | |||
| Assets Current | $922.0M | $951.0M | $883.0M | |||
| Accounts Payable And Accrued Liabilities Current | $215.0M | $196.0M | $183.0M | |||
| Repayments Of Long Term Debt | $4.0M | $1.0M | ||||
| Short Term Investments | $0.00 | $0.00 | $1.0M | |||
| Property Plant And Equipment Net | $124.0M | $117.0M | $104.0M | |||
| Other Liabilities Noncurrent | $30.0M | $18.0M | $17.0M | |||
| Other Liabilities Current | $0.00 | $0.00 | $3.0M | |||
| Operating Lease Right Of Use Asset | $30.0M | $35.0M | $37.0M | |||
| Operating Lease Liability Noncurrent | $24.0M | $29.0M | $30.0M | |||
| Operating Lease Liability Current | $10.0M | $11.0M | $11.0M | |||
| Long Term Investments | $28.0M | $27.0M | $27.0M | |||
| Long Term Debt Noncurrent | $304.0M | $308.0M | $311.0M | |||
| Long Term Debt Current | $18.0M | $18.0M | $18.0M | |||
| Intangible Assets Net Including Goodwill | $2.0M | $7.0M | $7.0M | |||
| Equity Securities Fv Ni Unrealized Gain Loss | ||||||
| Contract With Customer Refund Liability Current | $613.0M | $709.0M | $675.0M | |||
| Common Stock Value | $62.0M | $62.0M | $62.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$27.0M | $36.0M | -$300.0M | |
| Increase Decrease In Other Operating Liabilities | $41.0M | $8.0M | $110.0M | |
| Increase Decrease In Other Operating Assets | -$49.0M | -$377.0M | $418.0M | -$69.0M |
| Increase Decrease In Inventories | -$18.0M | $43.0M | $6.0M | $30.0M |
| Share Based Compensation | $26.0M | $24.0M | $21.0M | $16.0M |
| Proceeds From Sale And Maturity Of Held To Maturity Securities | $19.0M | $117.0M | $129.0M | $27.0M |
| Proceeds From Issuance Of Common Stock | $2.0M | $3.0M | $3.0M | $2.0M |
| Payments To Acquire Property Plant And Equipment | $66.0M | $29.0M | $8.0M | $5.0M |
| Payments To Acquire Intangible Assets | $1.0M | $2.0M | $45.0M | $0.00 |
| Payments To Acquire Held To Maturity Securities | $20.0M | $17.0M | $45.0M | $245.0M |
| Payments Related To Tax Withholding For Share Based Compensation | $5.0M | $22.0M | $22.0M | $10.0M |
| Payments For Repurchase Of Common Stock | $11.0M | $173.0M | $33.0M | $90.0M |
| Net Cash Provided By Used In Investing Activities | -$66.0M | $69.0M | -$95.0M | -$222.0M |
| Net Cash Provided By Used In Financing Activities | -$30.0M | -$102.0M | -$64.0M | -$101.0M |
| Increase Decrease In Estimated Litigation Liability | -$368.0M | -$387.0M | $50.0M | $197.0M |
| Increase Decrease In Accounts Receivable | -$3.0M | $1.0M | $33.0M | $21.0M |
| Depreciation Depletion And Amortization | $10.0M | $16.0M | $15.0M | $16.0M |
| Adjustments Related To Tax Withholding For Share Based Compensation | $5.0M | $22.0M | $22.0M | $10.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Net Cash Provided By Used In Operating Activities | $75.0M | -$37.0M |
| Increase Decrease In Other Operating Liabilities | $81.0M | $0.00 |
| Increase Decrease In Other Operating Assets | $18.0M | -$396.0M |
| Increase Decrease In Inventories | -$5.0M | $27.0M |
| Share Based Compensation | $6.0M | $6.0M |
| Proceeds From Sale And Maturity Of Held To Maturity Securities | $6.0M | $31.0M |
| Proceeds From Issuance Of Common Stock | $1.0M | $2.0M |
| Payments To Acquire Property Plant And Equipment | $5.0M | $2.0M |
| Payments To Acquire Intangible Assets | $0.00 | $1.0M |
| Payments To Acquire Held To Maturity Securities | $5.0M | $4.0M |
| Payments Related To Tax Withholding For Share Based Compensation | $3.0M | $20.0M |
| Payments For Repurchase Of Common Stock | $11.0M | $36.0M |
| Net Cash Provided By Used In Investing Activities | -$5.0M | $25.0M |
| Net Cash Provided By Used In Financing Activities | -$17.0M | -$56.0M |
| Increase Decrease In Estimated Litigation Liability | -$62.0M | -$486.0M |
| Increase Decrease In Accounts Receivable | -$11.0M | -$4.0M |
| Depreciation Depletion And Amortization | $5.0M | $5.0M |
| Adjustments Related To Tax Withholding For Share Based Compensation | $3.0M | $20.0M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Earnings Per Share Diluted | $1.64 | $0.05 | $-0.92 | ||
| Earnings Per Share Basic | $1.68 | $0.05 | $-0.92 | ||
| Weighted Average Number Of Shares Outstanding Basic | 125.0M | 132.0M | 137.0M | 139.0M | |
| Weighted Average Number Of Diluted Shares Outstanding | 128.0M | 133.0M | 137.0M | 139.0M | |
| Common Stock Shares Issued | 125.0M | 125.0M | 137.0M | 136.0M | 702.0M |
| Common Stock Par Or Stated Value Per Share | $0.50 | $0.50 | $0.50 | $0.10 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $0.33 | $0.14 | $0.38 | $0.16 | $-0.72 | $0.45 |
| Earnings Per Share Basic | $0.34 | $0.15 | $0.38 | $0.16 | $-0.72 | $0.45 |
| Weighted Average Number Of Shares Outstanding Basic | 125.0M | 125.0M | 124.0M | 132.0M | 135.0M | 136.0M |
| Weighted Average Number Of Diluted Shares Outstanding | 129.0M | 126.0M | 125.0M | 133.0M | 135.0M | 137.0M |
| Common Stock Shares Issued | 125.0M | 125.0M | 125.0M | |||
| Common Stock Par Or Stated Value Per Share | $0.50 | $0.50 | $0.50 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $26.0M | $24.0M | $21.0M | $16.0M |
| Investment Income Interest | $22.0M | $23.0M | $43.0M | $19.0M |
| Gain Loss Related To Litigation Settlement | -$3.0M | -$195.0M | -$239.0M | -$296.0M |
| Stock Repurchased And Retired During Period Value | $11.0M | $168.0M | $33.0M | $90.0M |
| Stock Issued During Period Value New Issues | $2.0M | $3.0M | $3.0M | $2.0M |
| Foreign Currency Transaction Gain Loss Before Tax | -$1.0M | $2.0M | $10.0M | $4.0M |
| Share Repurchase Commitment | $0.00 | $10.0M | $23.0M | |
| Other Nonrecurring Income Expense | -$3.0M | $4.0M | -$9.0M | -$8.0M |
| Litigation Reserve Noncurrent | $52.0M | $365.0M | $359.0M | |
| Litigation Reserve Current | $42.0M | $99.0M | $492.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $6.0M | $8.0M | $6.0M | $6.0M | $6.0M | $6.0M |
| Investment Income Interest | $6.0M | $6.0M | $4.0M | $5.0M | $6.0M | $7.0M |
| Gain Loss Related To Litigation Settlement | $0.00 | $0.00 | -$1.0M | -$36.0M | -$160.0M | $0.00 |
| Stock Repurchased And Retired During Period Value | $11.0M | $52.0M | $34.0M | $36.0M | ||
| Stock Issued During Period Value New Issues | $1.0M | $1.0M | $1.0M | $2.0M | ||
| Foreign Currency Transaction Gain Loss Before Tax | $1.0M | $1.0M | ||||
| Share Repurchase Commitment | $0.00 | $0.00 | $0.00 | |||
| Other Nonrecurring Income Expense | -$1.0M | $4.0M | ||||
| Litigation Reserve Noncurrent | $300.0M | $299.0M | $297.0M | |||
| Litigation Reserve Current | $106.0M | $105.0M | $105.0M |
Most recent annual filing with the SEC: February 26, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.